SeaStar Medical Holding Corp.

We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device ( SCD ) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. We received Food and Drug Administration ( FDA ) approval on February 21, 2024, under a Humanitarian Device Exemption ( HDE ) for our pediatric SCD therapy. It is the only FDA approved product for use in pediatric patients with acute kidney injury ( AKI ) due to sepsis or a septic condition requiring kidney replacement therapy. We shipped our first commercial pediatric SCD ( QUELIMMUNE ) in July 2024. In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy ( CRRT ). We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation. Our SCD therapy has been awarded six Breakthrough Device Designations ( BDD ) by the FDA.